<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450957</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02709</org_study_id>
    <secondary_id>UIC-2006-0853</secondary_id>
    <secondary_id>CDR0000536181</secondary_id>
    <secondary_id>N01CN85081</secondary_id>
    <nct_id>NCT00450957</nct_id>
  </id_info>
  <brief_title>Lycopene in Healthy Male Participants</brief_title>
  <official_title>Phase I Multiple Dose Pharmacokinetic Study of the Dietary Supplement Lycopene Delivered in Capsule Form to Healthy Male Volunteers Between 18 and 55 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase I trial is studying the side effects and best dose of lycopene in&#xD;
      healthy male participants. Chemoprevention is the use of certain drugs to keep cancer from&#xD;
      forming. The use of lycopene, a substance found in tomatoes, may prevent prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare the toxicity and safety of 2 different doses of oral lycopene in healthy male&#xD;
      participants.&#xD;
&#xD;
      II. Compare the pharmacokinetics of 2 different doses of this drug in these participants.&#xD;
&#xD;
      III. Determine the toxicity and pharmacokinetics needed to proceed to a large phase II/III&#xD;
      study in men at high risk for prostate cancer.&#xD;
&#xD;
      OUTLINE: This is a randomized, crossover study. Participants are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
      Arm I: Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2&#xD;
      weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the&#xD;
      alternative daily schedule (once or twice a day) for 14 days.&#xD;
&#xD;
      Arm II: Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2&#xD;
      weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the&#xD;
      alternative daily schedule (once or twice a day) for 14 days.&#xD;
&#xD;
      Treatment continues in the absence of unacceptable toxicity. Participants adhere to dietary&#xD;
      restrictions for 2 weeks at baseline, 2 weeks during study treatment, and 2 weeks during&#xD;
      pharmacokinetic sampling.&#xD;
&#xD;
      Blood samples are collected periodically at baseline and during study treatment for&#xD;
      pharmacokinetic studies.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity according to NCI Common Toxicity Criteria (CTC) version 3.0</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety according to NCI CTC version 3.0</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>At baseline, at 12, 24, 36, 48, 72, 96, 120, 168, 216, 288, and 360 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy, no Evidence of Disease</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (high-dose lycopene)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (low-dose lycopene)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lycopene</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (high-dose lycopene)</arm_group_label>
    <arm_group_label>Arm II (low-dose lycopene)</arm_group_label>
    <other_name>all-trans-Lycopene</other_name>
    <other_name>Lyc-O-Mato</other_name>
    <other_name>LYCO</other_name>
    <other_name>psi,psi-Carotene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (high-dose lycopene)</arm_group_label>
    <arm_group_label>Arm II (low-dose lycopene)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers judged to be in good medical condition based on history and&#xD;
             physical exam&#xD;
&#xD;
          -  Karnofsky performance status 100%&#xD;
&#xD;
          -  AST and ALT ≤ 75 IU/L&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Hemoglobin ≥ 13.0 g/dL&#xD;
&#xD;
          -  WBC ≥ 4,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 150,000/mm³ and ≤ 400,000/mm³&#xD;
&#xD;
          -  Must be within height and weight standards identified by Metropolitan Life scales&#xD;
&#xD;
          -  Nonsmoker (for ≥ 3 months)&#xD;
&#xD;
          -  No history of alcohol abuse&#xD;
&#xD;
          -  No history of gastrointestinal malabsorption or other condition that could affect drug&#xD;
             absorption&#xD;
&#xD;
          -  No history of a psychiatric condition&#xD;
&#xD;
          -  No chronic medical condition&#xD;
&#xD;
          -  No active history of any of the following:&#xD;
&#xD;
               -  Cancer&#xD;
&#xD;
               -  Liver disease&#xD;
&#xD;
               -  Cardiovascular disease&#xD;
&#xD;
               -  Renal disease&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Other illnesses that, in the opinion of the investigator, could represent a&#xD;
                  threat for the participants life&#xD;
&#xD;
          -  No allergy to tomato-based products&#xD;
&#xD;
          -  No lycopene in the diet for ≥ 14 days&#xD;
&#xD;
          -  At least 4 weeks since prior and no other concurrent experimental medications&#xD;
&#xD;
          -  No concurrent participation in another experimental study&#xD;
&#xD;
          -  No concurrent use of regular prescription medication or over-the-counter medications&#xD;
&#xD;
          -  No concurrent vitamin, mineral, or herbal supplements&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Rodvold</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

